The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 14, 2021

Filed:

Oct. 18, 2016
Applicant:

University of Massachusetts, Boston, MA (US);

Inventors:

Jack L. Leonard, Shrewsbury, MA (US);

Karl J. Simin, Princeton, MA (US);

Deborah M. Leonard, Shrewsbury, MA (US);

Assignee:

University of Massachusetts, Boston, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07K 14/47 (2006.01); A01K 67/027 (2006.01); A61K 33/243 (2019.01); A61P 35/00 (2006.01); C12N 15/86 (2006.01); A61K 31/337 (2006.01); A61K 31/351 (2006.01);
U.S. Cl.
CPC ...
A61K 48/005 (2013.01); A01K 67/0275 (2013.01); A61K 33/243 (2019.01); A61P 35/00 (2018.01); C07K 14/4703 (2013.01); A01K 2217/072 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); A61K 31/337 (2013.01); A61K 31/351 (2013.01); A61K 2300/00 (2013.01); C12N 15/86 (2013.01);
Abstract

The invention relates to the discovery of a vital new component of the Wnt pathway that regulates trafficking of β-catenin to the cell nucleus and novel therapeutic approaches to cancer treatment. Disclosed herein is a previously unknown, essential component of the Wnt/β-catenin signaling pathway that governs the quantity of β-catenin delivered to the cell nucleus. This intracellular inhibitor of β-catenin signaling (IBS) is transcribed from a second transcriptional start site adjacent to exon 3 of the Dkk3 gene and is required for early mouse development. IBS captures β-catenin destined for the nucleus in a complex with β-TrCP that is bound to the actin cytoskeleton and unavailable for nuclear translocation.


Find Patent Forward Citations

Loading…